MindBio Therapeutics (MBIO) | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Home
Companies
MindBio Therapeutics

BRIEF

published on 08/19/2024 at 13:25, 3 months 1 day ago

MindBio Reports Sustained Antidepressant Response Post Microdosing Treatment

Clinical Trials Microdosing LSD MindBio Therapeutics Mental Health Treatment Antidepressant Response
PRESS RELEASE

published on 08/19/2024 at 13:20, 3 months 1 day ago

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
MindBio reports sustained antidepressant response in depressed patients three months post MB22001 treatment. Excellent safety and efficacy shown in Phase 2A clinical trials

MindBio Phase 2A Clinical Trials Antidepressant Response MB22001 Treatment Sustained
BRIEF

published on 08/01/2024 at 11:25, 3 months 19 days ago

MindBio Therapeutics Appoints Haywood Securities for Strategic Investment Advisory

Psychedelic Medicine Strategic Investment Clinical Trials Mental Health Biopharmaceutical
PRESS RELEASE

published on 08/01/2024 at 11:20, 3 months 19 days ago

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
MindBio Therapeutics appoints Haywood Securities Inc. as strategic advisor to support investment initiatives. Company progressing with Phase 2B clinical trials for psychedelic medicine MB22001

Psychedelic Medicine Clinical Trials Investment MindBio Therapeutics Haywood Securities Inc.
BRIEF

published on 07/08/2024 at 14:25, 4 months 12 days ago

MindBio Therapeutics CEO Updates Shareholders on Clinical Trials Progress

Clinical Trials Mental Health MB22001 MindBio Psychiatric Medicine
PRESS RELEASE

published on 07/08/2024 at 14:20, 4 months 12 days ago

Mindbio Therapeutics CEO Issues Letter To Shareholders
MindBio Therapeutics Corp. issues shareholder update on Phase 2B clinical trials progress, focusing on treating Major Depressive Disorder & Advanced Stage Cancer - End of Life Distress related Depression and Anxiety with MB22001 drug

MindBio Therapeutics Corp. Major Depressive Disorder Phase 2B Clinical Trials MB22001 Drug Advanced Stage Cancer
BRIEF

published on 06/20/2024 at 12:15, 5 months ago

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

Depression Clinical Trials MB22001 Microdosing MindBio Therapeutics
PRESS RELEASE

published on 06/20/2024 at 12:10, 5 months ago

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
MindBio Therapeutics reports significant and sustained reduction in depression symptoms with MB22001 microdosing trials. Phase 2B trials show promise for mental health treatment

Depression MB22001 Microdosing MindBio Therapeutics Phase 2B Trials
BRIEF

published on 06/12/2024 at 10:25, 5 months 9 days ago

MindBio Therapeutics Reports Improvement in Depression Trial Outcomes

MB22001 Microdosing MindBio Therapeutics Depression Trial Psychiatric Medicine
PRESS RELEASE

published on 06/12/2024 at 10:20, 5 months 9 days ago

MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking microdosing depression trial with MB22001, showing significant reductions in anxiety, stress, and depression

MindBio Therapeutics Corp. MB22001 Microdosing Depression Trial Psychedelic Medicines Phase 2A Depression Trial

1 2 ... 5

Accesswire

Published on 11/21/2024 at 10:03, 27 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 30 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 30 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 55 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 5 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 25 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 28 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 30 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 30 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 29 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 32 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 10 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 45 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 45 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE